Revenue Breakdown
Composition ()
No data
Revenue Streams
Vericel Corp (VCEL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is MACI, accounting for 82.5% of total sales, equivalent to $55.66M. Other significant revenue streams include Epicel and NexoBrid. Understanding this composition is critical for investors evaluating how VCEL navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Vericel Corp maintains a gross margin of 78.70%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 24.12%, while the net margin is 25.01%. These profitability ratios, combined with a Return on Equity (ROE) of 5.11%, provide a clear picture of how effectively VCEL converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, VCEL competes directly with industry leaders such as PRGO and GLTO. With a market capitalization of $1.81B, it holds a significant position in the sector. When comparing efficiency, VCEL's gross margin of 78.70% stands against PRGO's 32.64% and GLTO's N/A. Such benchmarking helps identify whether Vericel Corp is trading at a premium or discount relative to its financial performance.
